{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007042","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.707191+00:00","generated_at":"2026-06-18T07:31:00.898146+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MindMed FY2022 net loss $56.8M; cash $142.1M; key MM-120 data readouts expected late 2023","bullets":["Net loss of $56.8M, improved from $93.0M in FY2021; no revenue (clinical-stage biopharma).","Cash and equivalents $142.1M vs $133.5M; cash runway into first half 2025.","R&D expenses $36.2M (up $1.4M); G&A $30.2M (down $28.9M, largely due to lower stock comp).","Phase 2b MM-120 GAD top-line data and Phase 2a MM-120 ADHD data both expected late 2023.","First clinical trial of MM-402 (R-MDMA for autism) planned for 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007042","json":"https://secwatch.observer/filing/0000950170-23-007042.json","markdown":"https://secwatch.observer/filing/0000950170-23-007042.md","text":"https://secwatch.observer/filing/0000950170-23-007042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/0000950170-23-007042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/mnmd-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:31:00.898146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b9eb701e3ad2fc56189090538611e4dde81132f","claim":"Definium Therapeutics, Inc. updated its the full-year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"today reported its financial results for the full-year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023007042/0000950170-23-007042-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}